Tenaya Therapeutics Inc
TNYA1.285USD
+0.065+5.33%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
209.42MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Tenaya Therapeutics Inc Unternehmen
Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. The Company is advancing a pipeline of novel therapies with diverse treatment modalities for rare genetic cardiovascular disorders and more prevalent heart conditions. The Company’s advanced product candidates include TN-201, TN-401, and TN-301. TN-201 is an adeno-associated virus serotype 9 (AAV9)-based gene therapy being developed to treat the underlying cause of MYBPC3 associated HCM by delivering a working MYBPC3 gene to specific cells of the heart via a single infusion. TN-401 is the Company’s adeno-associated virus serotype 9 (AAV9)-based gene therapy being developed for the treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) due to disease-causing variants in the PKP2 gene. TN-301 is a small molecule for heart failure with preserved ejection fraction.
Unternehmensinformationen
BörsenkürzelTNYA
Name des UnternehmensTenaya Therapeutics Inc
IPO-datumJul 30, 2021
CEOMr. Faraz Ali
Anzahl der mitarbeiter97
WertpapierartOrdinary Share
GeschäftsjahresendeJul 30
Addresse171 Oyster Point Blvd., Suite 500
StadtSOUTH SAN FRANCISCO
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl94080
Telefon14158652066
Websitehttps://www.tenayatherapeutics.com/
BörsenkürzelTNYA
IPO-datumJul 30, 2021
CEOMr. Faraz Ali
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Faraz Ali
Mr. Faraz Ali
Chief Executive Officer, Director
Chief Executive Officer, Director
82.91K
-14.91%
Dr. Catherine Stehman-Breen, M.D.
Dr. Catherine Stehman-Breen, M.D.
Independent Director
Independent Director
8.13K
--
Dr. Whittemore (Whit) Tingley, M.D., Ph.D.
Dr. Whittemore (Whit) Tingley, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Karah Parschauer, J.D.
Ms. Karah Parschauer, J.D.
Independent Director
Independent Director
--
--
Dr. R. Sanders (Sandy) Williams, M.D.
Dr. R. Sanders (Sandy) Williams, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Amy L. Burroughs
Ms. Amy L. Burroughs
Independent Director
Independent Director
--
--
Dr. June Lee, M.D.
Dr. June Lee, M.D.
Independent Director
Independent Director
--
--
Dr. David V. Goeddel, Ph.D.
Dr. David V. Goeddel, Ph.D.
Independent Director
Independent Director
--
--
Mr. Jeffrey T. (Jeff) Walsh
Mr. Jeffrey T. (Jeff) Walsh
Independent Director
Independent Director
--
--
Dr. Deepak Srivastava, M.D.
Dr. Deepak Srivastava, M.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Faraz Ali
Mr. Faraz Ali
Chief Executive Officer, Director
Chief Executive Officer, Director
82.91K
-14.91%
Dr. Catherine Stehman-Breen, M.D.
Dr. Catherine Stehman-Breen, M.D.
Independent Director
Independent Director
8.13K
--
Dr. Whittemore (Whit) Tingley, M.D., Ph.D.
Dr. Whittemore (Whit) Tingley, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Karah Parschauer, J.D.
Ms. Karah Parschauer, J.D.
Independent Director
Independent Director
--
--
Dr. R. Sanders (Sandy) Williams, M.D.
Dr. R. Sanders (Sandy) Williams, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Amy L. Burroughs
Ms. Amy L. Burroughs
Independent Director
Independent Director
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, Aug 23
Aktualisiert: Sat, Aug 23
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
The Column Group LP
5.77%
The Vanguard Group, Inc.
2.92%
Empery Asset Management, L.P.
2.89%
BlackRock Institutional Trust Company, N.A.
1.64%
Renaissance Technologies LLC
1.13%
Andere
85.66%
Aktionäre
Aktionäre
Anteil
The Column Group LP
5.77%
The Vanguard Group, Inc.
2.92%
Empery Asset Management, L.P.
2.89%
BlackRock Institutional Trust Company, N.A.
1.64%
Renaissance Technologies LLC
1.13%
Andere
85.66%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
6.64%
Venture Capital
6.33%
Investment Advisor/Hedge Fund
5.83%
Hedge Fund
2.39%
Individual Investor
0.70%
Research Firm
0.55%
Private Equity
0.28%
Family Office
0.18%
Andere
77.09%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
235
93.48M
57.36%
+20.23M
2025Q1
240
59.62M
37.68%
-6.11M
2024Q4
227
46.66M
58.78%
-21.29M
2024Q3
228
59.37M
75.30%
-7.13M
2024Q2
219
58.72M
74.83%
-7.58M
2024Q1
206
57.55M
73.35%
-12.34M
2023Q4
191
47.88M
70.30%
-10.62M
2023Q3
197
52.92M
79.61%
-6.27M
2023Q2
192
50.82M
77.84%
-5.65M
2023Q1
177
48.22M
74.02%
-17.43M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
The Column Group LP
49.31M
30.32%
+39.91M
+424.60%
May 07, 2025
The Vanguard Group, Inc.
4.08M
2.51%
+809.99K
+24.75%
Mar 31, 2025
Empery Asset Management, L.P.
8.73M
5.37%
+8.73M
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
4.95M
3.05%
-52.13K
-1.04%
Mar 31, 2025
Renaissance Technologies LLC
1.54M
0.95%
+1.54M
--
Mar 31, 2025
AQR Capital Management, LLC
775.66K
0.48%
+775.66K
--
Mar 31, 2025
Geode Capital Management, L.L.C.
1.38M
0.85%
+106.44K
+8.39%
Mar 31, 2025
Euclidean Capital, L.L.C.
1.02M
0.62%
--
--
Mar 31, 2025
Alphabet, Inc.
915.71K
0.56%
--
--
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Name
Anteil
Keine Daten
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
